{"id":8690,"date":"2018-07-26T14:54:17","date_gmt":"2018-07-26T13:54:17","guid":{"rendered":"https:\/\/www.nridigital.com\/?p=8690"},"modified":"2018-09-17T13:09:55","modified_gmt":"2018-09-17T12:09:55","slug":"us-approval-epidiolex-fuels-new-hope-cannabinoid-based-medicines","status":"publish","type":"post","link":"https:\/\/www.nridigital.com\/health\/us-approval-epidiolex-fuels-new-hope-cannabinoid-based-medicines\/","title":{"rendered":"US approval for Epidiolex fuels new hope for cannabinoid-based medicines"},"content":{"rendered":"<p>In June the US Food and Drug Administration approved the country&#8217;s <a href=\"http:\/\/pharma.nridigital.com\/pharma_aug18\/cannabinoids_breakthrough_signals_hope_for_epilepsy_treatment\">first cannabinoid-based drug<\/a>, Epidiolex, for treating seizures in two forms of severe epilepsy. Abi Millar asks what this milestone will mean for other cannabinoid-based medicines being developed in the country.   <\/p>\n","protected":false},"excerpt":{"rendered":"<p>In June the US Food and Drug Administration approved the country&#8217;s first cannabinoid-based drug, Epidiolex, for treating seizures in two forms of severe epilepsy. Abi Millar asks what this milestone will mean for other cannabinoid-based [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":8649,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[82],"tags":[247],"class_list":["post-8690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-featured"],"_links":{"self":[{"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/posts\/8690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/comments?post=8690"}],"version-history":[{"count":2,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/posts\/8690\/revisions"}],"predecessor-version":[{"id":9083,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/posts\/8690\/revisions\/9083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/media\/8649"}],"wp:attachment":[{"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/media?parent=8690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/categories?post=8690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nridigital.com\/wp-json\/wp\/v2\/tags?post=8690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}